SHANGHAI, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announced a distribution and marketing partnership with LEO Pharma for toripalimab in Europe. T…

Benzinga

New York

United States

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

Ad Fontes Media

Media Bias/Fact Check

SHANGHAI, Jan. 20, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biophar…

Financial Post

Leon Cooperman

Allianz

Canada

SHANGHAI, China I January 20, 2025 I Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announced a distribution and marketing partnership with LEO Pharma for toripalimab in Europe. This col…

pipelinereview

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe - Pipelinereview

Shanghai-based Junshi Biosciences has announced a partnership with Denmark’s LEO Pharma to distribute and commercialise the drug in Europe.

European Medical Journal

LEO Pharma to market Junshi Biosciences's toripalimab

Junshi Biosciences and TopAlliance are set to enter a collaboration with LEO Pharma to distribute and market toripalimab in Europe.

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics